{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Zewen Song"}, {"accession": "MS:1000589", "name": "contact email", "value": "ly981045@csu.edu.cn"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "the third xiangya hospital of central south university"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Zewen Song"}, {"accession": "MS:1000589", "name": "contact email", "value": "ly981045@csu.edu.cn"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Department of Oncology of the Third Xiangya Hospital of Central South University"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD023345/FeNTA_1.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD023345/FeNTA_2.raw"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD023345/Set of 4 files.msf"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD023345/TiO2_1.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD023345/TiO2_2.raw"}], "description": "Aberrant regulation of angiogenesis involves in the growth and metastasis of tumors, but angiogenesis inhibitors fail to improve overall survival of pancreatic cancer patients in previous phase III clinical trials. A comprehensive knowledge of the mechanism of angiogenesis inhibitors against pancreatic cancer is helpful for clinical purpose and for the selection of patients who might benefit from the inhibitors. In this work, multi-omics analyses (transcriptomics, proteomics and phosphoproteomics profiling) were carried to delineate the mechanism of anlotinib, a novel angiogenesis inhibitor, against pancreatic cancer cells.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/09/PXD023345"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD023345"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD023345"}], "instruments": [{"accession": "MS:1002523", "name": "Q Exactive HF"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Phosphoproteomics Data,anlotinib, pancreatic cancer"}], "modifications": [{"accession": "MOD:00696", "name": "phosphorylated residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "33748143"}, {"accession": "MS:1002866", "name": "Reference", "value": "Zhang X, Liu Y, Zhang Z, Tan J, Zhang J, Ou H, Li J, Song Z. Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature. Front Cell Dev Biol. 2021 9:649265"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Phosphoproteomics Data of pancreatic cancers cells treated with anlotinib"}